title: Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation.
abstract: A congenital dysfibrinogenemia, fibrinogen(Nieuwegein), was discovered in a young man without any thromboembolic complications or bleeding. A homozygous insertion of a single nucleotide (C) in codon Aalpha 453 (Pro) introduced a stop codon at position 454, which resulted in the deletion of the carboxyl-terminal segment Aalpha 454-610. The ensuing unpaired cysteine at Aalpha 442 generated fibrinogen-albumin complexes of different molecular weights. The molecular abnormalities of fibrinogen(Nieuwegein) led to a delayed clotting and a fibrin network with a low turbidity. Electron microscopy confirmed that thin fibrin bundles were organized in a fine network. The use of fibrinogen(Nieuwegein)-derived fibrin (fibrin(Nieuwegein)) in an in vitro angiogenesis model resulted in a strong reduction of tube formation. The ingrowth of human microvascular endothelial cells (hMVEC) was independent of alpha(v)beta(3), indicating that the reduced ingrowth is not due to the absence of the RGD-adhesion site at position Aalpha 572-574. Rather, the altered structure of fibrin(Nieuwegein) is the cause, since partial normalization of the fibrin network by lowering the pH during polymerization resulted in an increased tube formation. Whereas factor XIIIa further decreased the ingrowth of hMVEC in fibrin(Nieuwegein), tissue transglutaminase (TG), which is released in areas of vessel injury, did not. This is in line with the absence of the cross-linking site for TG in the alpha-chains of fibrinogen(Nieuwegein). In conclusion, this newly discovered congenital dysfibrinogenemia has a delayed clotting time and leads to the formation of an altered fibrin structure, which could not be cross-linked by TG and which is less supportive for ingrowth of endothelial cells.
authors.affiliation: Gaubius Laboratory, TNO-PG, Leiden, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Collen
authors.forename: A
authors.initials: A
authors.lastname: Maas
authors.forename: T
authors.initials: T
authors.lastname: Kooistra
authors.forename: F
authors.initials: F
authors.lastname: Lupu
authors.forename: J
authors.initials: J
authors.lastname: Grimbergen
authors.forename: F J
authors.initials: FJ
authors.lastname: Haas
authors.forename: D H
authors.initials: DH
authors.lastname: Biesma
authors.forename: P
authors.initials: P
authors.lastname: Koolwijk
authors.forename: J
authors.initials: J
authors.lastname: Koopman
authors.forename: V W
authors.initials: VW
authors.lastname: van Hinsbergh
mesh_terms: D000328:Adult; D000347:Afibrinogenemia / Q000235:genetics* / Q000473:pathology; D001704:Biopolymers; D002196:Capillaries / Q000473:pathology*; D002478:Cells, Cultured; D018388:Codon, Terminator; D004730:Endothelium, Vascular / Q000648:ultrastructure*; D005091:Exons / Q000235:genetics; D005337:Fibrin / Q000096:biosynthesis / Q000737:chemistry / Q000648:ultrastructure*; D015241:Fibrinogens, Abnormal / Q000737:chemistry* / Q000235:genetics; D006801:Humans; D008297:Male; D008854:Microscopy, Electron; D008970:Molecular Weight; D016254:Mutagenesis, Insertional; D018919:Neovascularization, Physiologic / Q000235:genetics*; D009842:Oligopeptides / Q000502:physiology; D010314:Partial Thromboplastin Time; D019030:Receptors, Vitronectin / Q000276:immunology / Q000502:physiology; D017384:Sequence Deletion; D013329:Structure-Activity Relationship; D011503:Transglutaminases / Q000378:metabolism
chemical_list: D001704:Biopolymers; D018388:Codon, Terminator; D015241:Fibrinogens, Abnormal; D009842:Oligopeptides; D019030:Receptors, Vitronectin; C422763:fibrinogen Nieuwegein; C047981:arginyl-glycyl-aspartic acid; D005337:Fibrin; D011503:Transglutaminases